Get the Stockscreener App
25.59
3.03%
-0.80
10x Genomics Inc stock is currently priced at $25.59, with a 24-hour trading volume of 1.38M.
It has seen a -3.03% decreased in the last 24 hours and a -16.92% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $26.47 pivot point. If it approaches the $25.44 support level, significant changes may occur.
Previous Close:
$26.39
Open:
$26.18
24h Volume:
1.38M
Market Cap:
$3.06B
Revenue:
$625.45M
Net Income/Loss:
$-264.30M
P/E Ratio:
-13.40
EPS:
-1.91
Net Cash Flow:
$-73.95M
1W Performance:
-3.03%
1M Performance:
-16.92%
6M Performance:
-35.93%
1Y Performance:
-50.96%
1D Range:
$25.46
$26.18
52W Range:
$24.60
$63.57
10x Genomics Inc Stock (TXG) Company Profile
Name
10x Genomics Inc
Sector
Industry
Phone
925 401 7300
Address
6230 Stoneridge Mall Road, Pleasanton, CA
10x Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10x Genomics Inc Stock (TXG) Latest News
Cathie Wood's ARK shuffles Teladoc, 10X Genomics stock positions - Investing.com Australia
Investing.com Australia
Azenta opens the doors to its new genomics laboratory in Oxford, UK - News-Medical.Net
News-Medical.Net
Amalgamated Bank Reduces Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Defense World
New lab brings genomics options closer to UK users - Labmate Online
Labmate Online
Jump Financial LLC Sells 42,052 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) Not Flying Under The Radar - Yahoo Lifestyle UK
Yahoo Lifestyle UK
10x Genomics Inc Stock (TXG) Financials Data
10x Genomics Inc (TXG) Revenue 2024
TXG reported a revenue (TTM) of $625.45 million for the quarter ending March 31, 2024, a +16.64% rise year-over-year.
10x Genomics Inc (TXG) Net Income 2024
TXG net income (TTM) was -$264.30 million for the quarter ending March 31, 2024, a -51.61% decrease year-over-year.
10x Genomics Inc (TXG) Cash Flow 2024
TXG recorded a free cash flow (TTM) of -$73.95 million for the quarter ending March 31, 2024, a +41.19% increase year-over-year.
10x Genomics Inc (TXG) Earnings per Share 2024
TXG earnings per share (TTM) was -$2.23 for the quarter ending March 31, 2024, a -45.75% decline year-over-year.
10x Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Feb 22 '24 |
Sale |
46.34 |
2,821 |
130,737 |
847,560 |
| Hindson Benjamin J. | See Remarks |
Feb 22 '24 |
Sale |
46.34 |
2,613 |
121,098 |
283,059 |
| McAnear Justin J. | Chief Financial Officer |
Feb 22 '24 |
Sale |
46.34 |
1,865 |
86,432 |
95,240 |
| Saxonov Serge | Chief Executive Officer |
Feb 15 '24 |
Sale |
48.87 |
5,000 |
244,332 |
850,381 |
| Saxonov Serge | Chief Executive Officer |
Feb 09 '24 |
Sale |
49.53 |
1,000 |
49,530 |
855,381 |
| Saxonov Serge | Chief Executive Officer |
Jan 16 '24 |
Sale |
45.24 |
4,000 |
180,956 |
856,381 |
| Hindson Benjamin J. | See Remarks |
Dec 28 '23 |
Option Exercise |
11.48 |
8,334 |
95,674 |
285,672 |
| Saxonov Serge | Chief Executive Officer |
Dec 27 '23 |
Option Exercise |
1.20 |
14,935 |
17,922 |
860,381 |
| Saxonov Serge | Chief Executive Officer |
Dec 14 '23 |
Sale |
55.03 |
2,000 |
110,065 |
845,446 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '23 |
Sale |
43.72 |
3,723 |
162,751 |
847,446 |
About 10x Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.
10.87%
1.02%
Cap:
|
Volume (24h):